KRAS inhibitor-37, identified by its CAS number 3058573-95-5, is a small molecule designed to target and inhibit the activity of the KRAS protein, which is often mutated in various cancers, particularly pancreatic, colorectal, and lung cancers. This compound is part of a broader class of targeted therapies aimed at disrupting the signaling pathways that promote tumor growth and survival. Characteristically, KRAS inhibitor-37 exhibits high specificity for the mutant forms of KRAS, which is crucial for minimizing off-target effects and enhancing therapeutic efficacy. The compound's mechanism of action typically involves binding to the KRAS protein, thereby preventing its interaction with downstream effectors involved in cell proliferation and survival. Additionally, KRAS inhibitor-37 may demonstrate favorable pharmacokinetic properties, such as good oral bioavailability and metabolic stability, which are essential for effective clinical application. Ongoing research and clinical trials are likely focused on evaluating its safety, efficacy, and potential combination strategies with other cancer therapies to improve patient outcomes.

KRAS inhibitor-37

3058573-95-5: KRAS inhibitor-37, identified by its CAS number 3058573-95-5, is a small molecule designed to target and inhibit the activity of the KRAS protein, which is often mutated in various cancers, particularly pancreatic, colorectal, and lung cancers. This compound is part of a broader class of targeted therapies aimed at disrupting the signaling pathways that promote tumor growth and survival. Characteristically, KRAS inhibitor-37 exhibits high specificity for the mutant forms of KRAS, which is crucial for minimizing off-target effects and enhancing therapeutic efficacy. The compound's mechanism of action typically involves binding to the KRAS protein, thereby preventing its interaction with downstream effectors involved in cell proliferation and survival. Additionally, KRAS inhibitor-37 may demonstrate favorable pharmacokinetic properties, such as good oral bioavailability and metabolic stability, which are essential for effective clinical application. Ongoing research and clinical trials are likely focused on evaluating its safety, efficacy, and potential combination strategies with other cancer therapies to improve patient outcomes.

KRAS inhibitor-37 (compound 2) is a potent inhibitor of KRAS, exhibiting low dissociation constants (KD) with various KRAS mutations: wild type (0.004 nM), G12D (0.041 nM), G12C (0.019 nM), and G12V (0.144 nM). This compound effectively inhibits cell proliferation, demonstrating half-maximal inhibitory concentrations (IC50) ranging from <2 nM to 14 nM in H358, SW620, and PANC08.13 cell lines. KRAS inhibitor-37 holds potential for cancer research applications.

CAS 3058573-95-5

KRAS inhibitor-37

KRAS inhibitor-37

Ref: TM-T201259